Optimal results in certain areas may necessitate more than one syringe
Author: Noelia Rivera-Gonzlez, MS, RD, LDN, CDCES | CCS Health This site is for educational purposes only
Phase 2 (Jastreboff et al., NEJM 2023) reported 24.2% weight loss at 48 weeks at 12 mg
The balance between central efficacy and tolerability remains a key consideration as dual and triple agonists, targeting GIP and glucagon receptors (GCGRs) in addition to GLP-1, enter clinical use [27,44]
Your Healthy Weight Loss Is Our Goal The doctors at Signature Healthcare can work with you to determine if a weight loss treatment program is appropriate
Bruising after Zepbound (tirzepatide) injections is a common concern for patients starting this medication